Fig. 5
Evaluation of AIB5P treatment in multiple clinical bone loss/defect models. a Representative micro-CT of femurs from the OVX mice that received treatment with AIB5P (100 μg·kg−1, every 3 days, intravenous, total 1.5 months) or the known bone-formation-stimulating parathyroid hormone (PTH) (80 μg·kg−1, every 3 days, subcutaneous). Upper and middle panel, bar, 1 mm. Lower panel, bar, 500 μm. b Quantification of BMD, Tb.N, and BV/TV by micro-CT analysis. n = 6. c, d High-magnification images and quantification of calcein and xylenol orange double labeling of femur sections. Samples from six mice were used. e Upper, representative micro-CT images of femurs. Lower, representative micro-CT r statistics. Bar, 50 images of callus. Bar, 1 mm. f Quantification of BV/TV in callus. n = 6. g, h Representative H&E staining and anti-DMP1 IHC staining images of fractured femur sections. Bar, 200 μm. i Representative micro-CT images of vertical sections of implants (osteointegration model) treated with AIB5P (every 3 days, 100 μg·kg−1, intravenous, 3 weeks) or vehicle. The white circle line indicates the horizonal section position. Lower, cross-sectional view of bone formation surrounding the implant. Bar, 1 mm. j Quantification of new bone thickness on the implant surface. n = 6. k Van Gieson staining and bone quantification of the midshaft surface of implants. Bone surface per titanium implant surface (B.S./Ti.S.). Bar, 100 μm. n = 6. l von Kossa staining images and relative quantification of new bone formation in the implant model. Bar, 100 μm. n = 6
